Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Belite BioFRA:D01 -2.99%19 3-1 Month Momentum % is 8.80% as of Aug. 31, 2026. GuruFocus rates FRA:D01 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, Belite Bio ranks better than 74.95% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-31), Belite Bio's 3-1 Month Momentum % is 8.80%.
The industry rank for Belite Bio's 3-1 Month Momentum % or its related term are showing as below:
FRA:D01's 3-1 Month Momentum % is ranked better than 74.95% of 1385
companies
in the Biotechnology industry
Industry Median: -9.14
vs FRA:D01: 8.80
Belite Bio (FRA:D01) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Belite Bio 3-1 Month Momentum % Related Terms
FRA:D01 vs ORKA, TVTX, COGT: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Belite Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Belite Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Belite Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Belite Bio's 3-1 Month Momentum % falls into.
Belite Bio (FRA:D01) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Belite Bio (FRA:D01) has a 3-1 Month Momentum % of 8.80% as of Aug. 31, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Belite Bio and its competitors. According to the industry distribution chart, Belite Bio ranks #347 out of 1385 companies in the Biotechnology industry, placing it in the top 25.1%.
Is Belite Bio's 3-1 Month Momentum % too high?
Belite Bio's current 3-1 Month Momentum % is 8.80%. Based on the distribution chart, Belite Bio ranks #347 out of 1385 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Belite Bio has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's 3-1 Month Momentum % compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, Belite Bio ranks #347 out of 1385 companies for 3-1 Month Momentum %. This puts Belite Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Belite Bio and its competitors. Belite Bio's current 3-1 Month Momentum % is 8.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (FRA:D01) has a current 3-1 Month Momentum % of 8.80%. The current 3-1 Month Momentum % is 8.80%. Belite Bio's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Belite Bio (FRA:D01), the current 3-1 Month Momentum % is 8.80% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
19GF Score
Get the complete analysis for FRA:D01
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D01 has been successfully added to your 
